A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors
- 12 October 2010
- journal article
- phase i-studies
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 30 (2), 629-638
- https://doi.org/10.1007/s10637-010-9563-7
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemiasHaematologica, 2010
- Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative DisordersJournal of Clinical Oncology, 2010
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk DiseaseJournal of Clinical Oncology, 2009
- Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid TumorsClinical Cancer Research, 2009
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaBlood, 2009
- Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid TumorsClinical Cancer Research, 2007
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006
- Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805Clinical Cancer Research, 2005
- Seventy-Two Hour Continuous Infusion Flavopiridol in Relapsed and Refractory Mantle Cell LymphomaLeukemia & Lymphoma, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000